高通量测序技术检测Sabin株脊髓灰质炎病毒突变率方法的建立及应用
收稿日期: 2026-02-26
修回日期: 2026-06-08
录用日期: 2026-06-28
网络出版日期: 2026-10-09
基金资助
国家科技重大专项创新疫苗评价与质量控制(2025ZD01903805)
Establishment and Application of A Method for Detecting the Mutation Rate of Sabin-Strain Poliovirus by High-Throughput Sequencing Technology
Received date: 2026-02-26
Revised date: 2026-06-08
Accepted date: 2026-06-28
Online published: 2026-10-09
目的:建立基于高通量测序技术的Sabin株脊髓灰质炎病毒中关键基因位点突变率的检测方法,并采用MAPREC国际标准品验证方法的准确性,应用于Sabin株脊髓灰质炎病毒的质量控制。方法:提取Sabin株脊髓灰质炎病毒基因,基因组测序文库构建后进行高通量测序,分析神经毒力相关基因位点的突变率,并对方法的准确度、精密度进行评价。结果:成功建立3个型别Sabin株脊髓灰质炎病毒中关键基因位点突变率检测方法。对3个型别6种Sabin株病毒突变标准品的检测结果显示,回收率为71.4%~107.3%。精密度验证结果显示,变异系数(CV)为2.14%~14.52%。采用本方法对Sabin株脊髓灰质炎病毒工作种子及收获液进行检测,均符合WHO要求。结论:高通量测序技术检测3个型别Sabin株病毒突变率的结果与MAPREC法相当,且该方法可靠性好、准确度与精密度较高,可作为MAPREC法的替代方法用于Sabin株脊髓灰质炎减毒活疫苗(OPV)及脊髓灰质炎灭活疫苗(IPV)的质量控制。
关键词: 高通量测序; Sabin株脊髓灰质炎病毒; 疫苗; 突变率; 质量控制
徐康维
.
高通量测序技术检测Sabin株脊髓灰质炎病毒突变率方法的建立及应用
Objective: To establish a method for detecting the mutation rate of key gene loci in Sabin-strain poliovirus based on high-throughput sequencing technology, evaluate the accuracy of this method using MAPREC international reference materials, and apply it to the quality control of Sabin-strain poliovirus.Methods: The genes of Sabin-strain poliovirus were extracted, and after the construction of genomic sequencing libraries, high-throughput sequencing was performed. The mutation rates of gene loci related to neurovirulence were analyzed, and the accuracy and precision of the method were evaluated.Results: A method for detecting the mutation rate of key gene loci in three serotypes of Sabin-strain poliovirus was successfully established. The detection results of 6 types of mutation reference materials covering three serotypes of Sabin-strain poliovirus showed that the recovery rate ranged from 71.4% to 107.3%. The precision verification results demonstrated that the coefficient of variation (CV) was between 2.14% and 14.52%. The detection results of Sabin-strain poliovirus working seeds and harvest fluids using this method all met the requirements of the World Health Organization (WHO).Conclusion: The results of detecting the mutation rate of three serotypes of Sabin-strain poliovirus by high-throughput sequencing technology are comparable to those of the MAPREC method. This method features good reliability, as well as high accuracy and precision,and can be used as an alternative to the MAPREC method for the quality control of Sabin-strain oral poliovirus vaccine (OPV) and inactivated poliovirus vaccine (IPV).
[1] Mbani CJ, Nekoua MP, Moukassa D, et al. The fight against poliovirus is not over[J].Microorganisms, 2023,11(5):1323.
[2] Quarleri J. Poliomyelitis is a current challenge:long-term sequelae and circulating vaccine-derived poliovirus[J].Geroscience, 2023,45(2):707-717.
[3] Russo GB, Goyal T, Tyler K, et al. Re-emergence of poliovirus in the United States:considerations and implications[J].Ann Neurol, 2022,92(5):725-728.
[4] Uwishema O, Eneh SC, EL Jurdi E, et al. Poliovirus returns to the UK after nearly 40 years: current efforts and future recommendations[J].Postgrad Med J, 2022,98(1165):816-819.
[5] Kang Guodong, Tang Feng, Wang Zhong, et al. Surveillance of adverse events following the introduction of inactivated poliovirus vaccine made from Sabin strains (sIPV) to the Chinese EPI and a comparison with adverse events following inactivated poliovirus vaccine made from wild strains (wIPV) in Jiangsu, China[J].Hum Vaccin Immunother, 2021,17(8):2568-2574.
[6] Liu Yafei, Liu Xiaodong, Zhang Li, et al. Safety and immunogenicity of sIPV in healthy infants aged 2 months following sequential immunization program combination with bOPV: a phase 3, randomized, blinded, parallel positive-controlled clinical trial[J].Vaccines (Basel), 2025,13(11):1094.
[7] Fan Chunxiang, Li Keli, Zhang Lina, et al. Surveillance for adverse events following immunization with domestic sabin-strain inactivated poliovirus vaccine - China,2015-2022[J].China CDC Wkly, 2024, 6(50): 1313-1318.
[8] Feng Guangwei, Shao Ming, Wang Jianfeng, et al.Immune persistence following primary immunization and the immunogenicity and safety of a booster dose of a multidose sabin strain-based inactivated polio vaccine in infants aged 18 months[J].Vaccines (Basel), 2024, 12(2): 123.
[9] Chu Kai, Li Yurong, Liu Sheng,et al. Sustained immune persistence five years post-completion of four-dose sIPV vaccination[J].Vaccines (Basel), 2025, 13(3):253.
[10] 徐康维,张平,英志芳,等.定量检测Ⅲ型Sabin株脊髓灰质病毒突变的荧光MAPREC法的建立和应用[J].药物分析杂志,2018,38(2):288-292.
[11] 徐康维,张平,英志芳,等.荧光MAPREC分析Ⅰ型Sabin株脊髓灰质炎病毒突变率方法的建立和应用[J].微生物学免疫学进展,2017,45(6):56-60.
[12] Simsek C, Bloemen M, Jansen D, et al. Rotavirus vaccine-derived cases in belgium: evidence for reversion of attenuating mutations and alternative causes of gastroenteritis[J].Vaccine,2022, 40(35): 5114-5125.
[13] Pasik K, Domańska-Blichaarz K. High-throughput sequencing in vaccine research[J].J Vet Res, 2021,65(2):131-137.
[14] Alston A, Bova RA, Hasson B. Validation of a next generation sequencing method for adventitious agents detection in a live vaccine matrix[J].Biologicals, 2025,90:101828.
[15] Quer J, Colomer-castell S, Campos C, et al. Next-generation sequencing for confronting virus pandemics[J].Viruses, 2022,14(3): 521.
[16] Charlton B, Hockley J, Laassri M, et al. The use of next-generation sequencing for the quality control of live-attenuated polio vaccines[J].J Infect Dis, 2020,222(11):1920-1927.
[17] Lu Zhengbin, Douthitt MP, Taffs RE, et al. Quantitative aspects of the mutant analysis by PCR and restriction enzyme cleavage (MAPREC)[J].PCR Methods Appl, 1993,3(3):176-180.
[18] Chumakov KM, Powers LB, Noonan KE, et al. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine[J].Proc Natl Acad Sci USA, 1991,88(1):199-203.
[19] Sarcey E, Serres A, Tindy F, et al. Quantifying low-frequency revertants in oral poliovirus vaccine using next generation sequencing[J].J Virol Methods, 2017,246:75-80.
/
| 〈 |
|
〉 |